This announcement is a separate document:
大塚ホールディングス：新規APRIL抗体「シベプレンリマブ」IgA腎症を対象としたフェーズ3試験の良好な中間解析結果について
Otsuka Holdings: Good interim analysis results of the phase 3 trial targeting the novel APRIL antibody “sibeprenlimab” IgA nephropathy
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated